Study Evaluating Venlafaxine Extended Release in Elderly Depressed Patients

Completed

• Conditions: Anxiety; Depressive Syndrome

• Registration Number: NCT00247429
• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Brief Summary

In this study we will assess as a primary objective the effect of venlafaxine retard treatment on primary care attended elderly patients with depressive syndrome. We will also study secondarily its effects on anxiety, somatic and painful symptoms of depression.

Detailed Description

Not available

Study Timeline

• Study Start: 2004-07
• Primary Completion: 2005-10
• Study Completion: 2005-10
• Study First Submitted: 2005-10-28
• Study First Submitted QC: 2005-10-28
• Study First Posted: 2005-11-01
• Status Verified: 2009-08
• Last Update Submitted: 2009-08-31
• Last Update Posted: 2009-09-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 59

Inclusion Criteria

• Patients older than 60 years
• Depressive syndrome with associated anxiety symptoms, according to a symptoms intensity HAM-D17³14

Exclusion Criteria

• Participation in other studies in the last 3 months before the start of the study
• Known hypersensibility to venlafaxine
• Clinically significant abnormalities according to the venlafaxine labeling

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified